Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis

BACKGROUND: Targeting the mammalian target of rapamycin by everolimus is a successful approach for renal cell carcinoma (RCC) therapy. The Toll-like receptor 9 agonist immune modulatory oligonucleotide (IMO) exhibits direct antitumour and antiangiogenic activity and cooperates with both epidermal gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Damiano, V, Rosa, R, Formisano, L, Nappi, L, Gelardi, T, Marciano, R, Cozzolino, I, Troncone, G, Agrawal, S, Veneziani, B M, De Placido, S, Bianco, R, Tortora, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668470/
https://www.ncbi.nlm.nih.gov/pubmed/23571736
http://dx.doi.org/10.1038/bjc.2013.153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668470/
https://www.ncbi.nlm.nih.gov/pubmed/23571736
http://dx.doi.org/10.1038/bjc.2013.153

Ejemplares similares